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Abstract
Background: Hypersensitivity reactions against nonsteroidal antiinflammatory drugs (NSAIDs) like diclofenac (DF) can
manifest as Type I-like allergic reactions including systemic anaphylaxis. However, except for isolated case studies
experimental evidence for an IgE-mediated pathomechanism of DF hypersensitivity is lacking. In this study we aimed to
investigate the possible involvement of drug- and/or metabolite-specific antibodies in selective DF hypersensitivity.
Methodology/Principal Findings: DF, an organochemically synthesized linkage variant, and five major Phase I metabolites
were covalently coupled to carrier proteins. Drug conjugates were analyzed for coupling degree and capacity to crosslink
receptor-bound IgE antibodies from drug-sensitized mice. With these conjugates, the presence of hapten-specific IgE
antibodies was investigated in patients’ samples by ELISA, mediator release assay, and basophil activation test. Production
of sulfidoleukotrienes by drug conjugates was determined in PBMCs from DF-hypersensitive patients. All conjugates were
shown to carry more than two haptens per carrier molecule. Immunization of mice with drug conjugates induced drug-
specific IgE antibodies capable of triggering mediator release. Therefore, the conjugates are suitable tools for detection of
drug-specific antibodies and for determination of their anaphylactic activity. Fifty-nine patients were enrolled and
categorized as hypersensitive either selectively to DF or to multiple NSAIDs. In none of the patients’ samples evidence for
drug/metabolite-specific IgE in serum or bound to allergic effector cells was found. In contrast, a small group of patients (8/
59, 14%) displayed drug/metabolite-specific IgG.
Conclusions/Significance: We found no evidence for an IgE-mediated effector mechanism based on haptenation of protein
carriers in DF-hypersensitive patients. Furthermore, a potential involvement of the most relevant metabolites in DF
hypersensitivity reactions could be excluded.
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Introduction
Diclofenac (DF) is one of the most popular drugs world-wide
belonging to the family of nonsteroidal antiinflammatory drugs
(NSAIDs). Adverse drug reactions (ADRs), which occur in about
every fifth patient, are well-known side effects mainly caused by
the NSAIDs’ acidic properties [1]. More serious are drug
hypersensitivity reactions (DHRs) to DF, which clinically manifest
as Type-I-like allergic reactions with sudden and unpredictable
occurrence and can progress into anaphylactic shock. Two
pathomechanisms are currently thought to be involved in NSAIDs
hypersensitivity reactions: (i) multiple NSAIDs hypersensitivity
(also those involving DF) has been considered as pharmacokinetic
disorders due to non-selective coinhibition of cyclooxygenase
(COX)-1 leading to shifts in the prostaglandin and leukotriene
levels [2,3]; (ii) in contrast, for selective NSAID hypersensitivities
including DF, an involvement of the immune system is still being
postulated [4]. Accordingly, drug-specific IgE has been reported in
patients with DHRs to ASA, ibuprofen [5], propyphenazone [6],
and sporadically to DF [7,8]. Nevertheless, skin tests in DF-
hypersensitive patients have persistently given negative results.
Therefore, it is conceivable that various bioactivation and
haptenation processes may play a role in DF hypersensitivity.
However, adequate reagents for skin testing or in vitro assays are
not available despite the fact that several Phase I metabolites of DF
have been identified in human plasma, bile, and urine [9]. In
addition, DF Phase II metabolites have been described in
hepatocyte cultures [10]. The ability of Phase I metabolites to
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studies [11,12] and in cases of DF-induced immune hemolytic
anemia [13]. Although protein conjugates of Phase II metabolites
have not been described, it is possible that reactive intermediates
of DF might haptenize to proteins in an alternative orientation.
In this study we performed a detailed investigation of drug-
specific antibody responses in patients suffering from selective
DHRs to DF. The possible role of drug-metabolism and
bioactivation was examined using five major Phase I metabolites
and one linkage variant of DF as haptens. The presence of drug/
metabolite-specific IgE antibodies was investigated in serum and
on basophils isolated from patients.
Materials and Methods
Ethics statement
The study was approved by the Ethics Committee for
Experiments Involving Humans and/or Animals at the University
of Salzburg complying with the Helsinki Declaraction as revised in
1983 and all patients participating gave their written informed
consent.
Mice were maintained in the animal facility at the University of
Salzburg and all animal experiments were conducted according to
National guidelines approved by the Austrian Ministry of Science
(BMWF-66.012/0011-II/10b/2010). The protocol was approved
by the Ethics Committee for Experiments Involving Humans and/
or Animals at the University of Salzburg. Blood drawals were done
from the tail vein making all efforts to minimize suffering.
Study population and clinical characterization
From 2005-2008, 59 patients (36 female, 23 male; mean age
53.9) with a history of acute hypersensitivity to DF (anaphylaxis I-
IV, classification according to Ring and Messmer [14]) referred to
the allergy centers of the university hospitals of Salzburg and Graz
were studied. Patients underwent detailed clinical history and
subjects with aspirin-exacerbated respiratory disease or chronic
urticaria as underlying diseases were excluded. Characterization
included skin tests, determination of total serum IgE and allergen-
specific IgE against common aeroallergens (SX1, Phadia, Uppsala,
Sweden) and 48 patients also underwent oral provocation testing
(OPT). OPT was performed by a medical doctor in a single blind
way with increasing dosage up to a usual single dose and
administration intervals of at least 1.5 hours. The total dose was
up to a normal daily dose. Patients were under continuous
observation with emergency medication at hand and were told to
report any occurring symptoms immediately. IgE measurements
were carried out by ImmunoCAP
TM with ,100 kU/L total IgE
considered normal and .0.35 kU/ml specific IgE considered
positive. Six individuals (4 females, 2 males; mean age 38.7) who
tolerated DF upon repeated administration within 2 years before
analysis were included as controls.
Hapten-carrier conjugates
DF sodium salt (Sigma, St. Louis, MO) or five Phase I
metabolites (39OH-DF, 49OH-DF, 5OH-DF, 39OH49metO-DF,
and 495diOH-DF, Novartis-Pharma, Basel, CH) were covalently
coupled to human serum albumin (HSA) or keyhole limpet
hemocyanin (KLH) using N-(3-Dimethylaminopropyl)-N’-ethyl-
carbodiimide hydrochloride (EDC) in a molar ratio protein:hap-
ten:EDC of 1:100:100 for HSA conjugates and in a weight ratio of
1:1:0.25 for KLH conjugates.
A position-5 derivative of DF (DF5der) with a six C-atoms spacer
containing an aldehyde group was synthesized as described [15–17].
Sodium cyanoborohydride (NaBH3CN, Sigma) was used for
coupling DF5der to HSA in a molar ratio protein:hapten:NaBH3CN
of 1:20:100 and to KLH in a weight ratio of 1:0.3:0.1. HSA-mock
conjugates were produced analogously without addition of hapten
and used as negative controls.
The coupling degrees of DF/DF5der/DF-metabolites to HSA
(DF/HSA) were determined by High-Performance Size-Exclusion
Chromatography (HPSEC) online coupled with a triple detector
array (TDA302, Viscotek, Houston, TX, USA) as described
elsewhere [18] with 100 mg conjugate on column. Detector was
calibrated with HSA and values for dn/dc of 0.185 ml/g, dA/dc
of 0.518 ml/g, and molecular weight of 66472 were set [19]. For
all haptens dn/dc of 0.285 ml/g and dA/dc of 44.602 ml/g were
determined from the quotients of refractive index (RI) and UV280
areas by the amounts DF injected. The concentrations of HSA and
DF of eluting fractions were determined by following equations:
RI area = kRI[(dn/dc)HSA*cHSA+(dn/dc)DF*cDF]; UV280 area =
kUV[(dA/dc)HSA*cHSA+(dA/dc)DF*cDF].
DF/DF5der/DF-metabolite-specific antisera
Female BALB/c mice (Charles River Laboratories, Wilming-
ton, MA, USA) at 6 to 12 weeks of age were used to obtain
polyclonal antisera. Animals were injected subcutaneously (s.c.)
with with 5 mg DF/DF5der/DF-metabolite-KLH adsorbed to
Alugel-S (Serva, Heidelberg, Germany) given as two 50 ml s.c.
injections administered bilaterally in the lumbar region and
boosted on day 14, 21, and 42. Sera were collected one week after
a final boost and stored at 220uC until analysis.
Mediator release assays
Release assay with mouse sera (mRBL): Beta-hexosaminidase
release assays were performed with DF/DF5der/DF metabolite-
specific mouse antisera (final dilution 1:10) using RBL-2H3 cells
(ATCC: CRL-2256
TM) and the respective HSA conjugates
(varying concentrations), according to a protocol previously
described [20].
Release assay with human sera (huRBL): Patients’ sera were
tested with the RBL-703/21 cells (optimized subclone of RBL-30/
25 [21]), expressing the alpha-chain of the human high-affinity IgE
receptor (FceRI). HuRBL was performed as the mRBL assay with
the following modifications: cell attachment (10
5 cells/well) and
passive sensitization with human sera (1:10) were combined in an
overnight (ON) incubation step and stimulation buffer contained
50% D2O (Sigma) for enhancement of release. Crosslinking was
induced by addition of 1 mg/ml HSA conjugate. In patients with
severe (grade III and IV) and immediate (,30 min) reactions
crosslinking was measured for 12.5, 2.5, 0.25 mg/ml, 25, 2.5,
0.25 ng/ml HSA conjugate.
Cut-off was set at the mean percent release of negative controls
(mock-HSA) plus 3 times the standard deviation (3*SD). Interassay
performance of RBL-703/21 cells was controlled with serum from
a birch-allergic donor (1:10) and recombinant Bet v 1a (4 ng/ml).
Possible nonspecific effects were controlled by stimulating cells
with mock-HSA in both assay formats.
ELISA
Plates were coated with 2.5, 1.0, and 0.25 mg/well DF/
DF5der/DF-metabolite-HSA conjugates or mock-HSA. After
washing and blocking, 50 ml patient sera (1:2 and 1:10) diluted
in 25 mM tris-buffered saline pH 7.4, 0.05% Tween 20, 0.5%
BSA were added and incubated (ON, 4uC). Extensive washing was
followed by incubation (2 h, RT) with 50 ml alkaline phosphatase
(AP)-labeled anti-human IgE (1:2000, BD Pharmingen, Schwe-
chat, Austria), mouse anti-human IgG1 (hinge)-AP or anti-human
IgG4-AP (each 1:1000, Southern Biotech, AL, USA). For
No IgE in DF Hypersensitivity
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diethanolamine, 1 mM MgCl2, pH 9.5 were added and absor-
bance (405/492 nm) was measured after 0.5, 1, 2, and 3 h. Results
were analyzed from 3 h measurements and cut-off was determined
as mean absorbances plus 3*SD of mock-HSA. Values above
background were considered positive when absorbance index (AI;
absorbance test/absorbance individual negative control) .2, and
when reproducible in two independent assays.
Basophil activation test (BAT)
Basophil activation was performed from EDTA-whole blood
using Flow2CAST (Bu ¨hlmann Laboratories, Scho ¨nenbuch, CH)
according to the manufacturer’s protocol. Whole blood samples
were stimulated (20 min, 37uC) with HSA conjugates or mock-
HSA at a final concentration of 1 mg/ml. Processed samples were
immediately analyzed by flow cytometry (FACSCanto
TM II, BD
Bioscience, San Jose, CA) using FACSDiva 5.02. Basophils were
gated as SSC
low/CCR3
high and 500–1000 events recorded.
Activated basophils were identified as CD63
high and cut-off was
set with the negative stimulation control. Samples were considered
positive at activation percentage .5% CD63
high cells and
stimulation index (SI; % activated basophils divided by %
activated basophils of the negative stimulation control) .2.
Cytotoxicity of DF/DF5der/DF-metabolite conjugates was
investigated by costimulating samples with 1 or 20 mg/ml HSA
conjugates plus 10 mg/ml anti-human IgE (20 min, 37uC).
Basophil reactivity of the costimulated samples was calculated as
percentage of activated basophils upon stimulation with anti-
human FceRI antibody taken as 100% anti-IgE reactivity.
Cellular antigen stimulation test (CAST)
Antigen-induced production of sulfidoleukotrienes (sLTs) was
investigated using CAST-2000-ELISA (Bu ¨hlmann Laboratories)
according to manufacturer’s instructions. Cells were stimulated
with 1 mg/ml (final concentration) HSA conjugate or mock HSA.
Supernatants were collected after short centrifugation and stored
at 220uC until use. Samples were analyzed in duplicates and
results calculated with the 4-parameter-curve-fit option of
Deltasoft IIIv2.248 (BioMetallics, Princetown, NJ, USA). Sulfido-
leukotrienes were considered significantly increased when above
163.8 pg/ml, a cut-off that was calculated from the mean plus
3*SD of negative stimulation controls (patient #54 excluded
because of high background).
Results
Defining phenotypes of DF-hypersensitive patients
In this study, 59 patients with acute hypersensitivity to DF were
recruited (Table S1). In order to exactly define the patterns of
reactivity of patients towards DF and other NSAIDs 41 patients
underwent OPTs with various NSAIDs, but not with DF, seven
patients were challenged with DF, and for eleven patients
definition of clinical reactivity was based on history alone.
Accordingly, patients were divided into two groups: individuals
reporting an intolerance reaction exclusively to DF or tolerating
other NSAIDs in OPT were considered monosensitive to DF (DF
patients, n=41); patients reacting with other NSAIDs in OPT or
reporting an intolerance reaction to NSAIDs were classified as
multiple NSAIDs-reactive (NSAIDs patients, n=18). 48% (20/41)
of DF patients showed anaphylactic reactions with severity grades
III and IV. Onset of symptoms was immediate (#1 h) in 22/41
cases, accelerated (#12 h) in 12/41, and not specified in 5/41. In
contrast, 83% (15/18) of NSAIDs patients displayed severity grade
I or II reactions. Non-immediate onset of symptoms was no
exclusion criterium for this study as delays have been observed in
verified IgE-mediated reactions and suggested to result from
several factors including drug metabolism [22].
Skin test results were positive for three patients, two reacting
exclusively with DF (DF patient #59, NSAIDs patient #55) and
one with various NSAIDs (ASA, ibuprofen, metamizole, oxicams,
NSAIDs patient #31) but not with with DF. Parameters of atopy
showed no differences between DF and NSAIDs patients with
increased levels (.100 kU/l) of total IgE in 29% and 35% and
with specific IgE against inhalant allergens (SX1) in 22% and 20%
of the patients, respectively.
Physicochemical and functional characterization of
hapten-HSA conjugates
Human serum albumin was chosen for chemical conjugation of
DF/DF5der/DF-metabolites (Figure 1) as it is the most abundant
plasma protein and a physiological carrier of slightly acidic
xenobiotics like DF [23]. Mock-HSA was used to control for a
formation of neoepitopes, which might result from inter- and
intramolecular crosslinkings. Antigenic bivalency as minimum
theoretical requirement for a receptor cross-linking activity was
given as coupling degrees were shown to exceed 2 DF/HSA in all
conjugates as determined from the ratio of UV to RI signals from
HPSEC (Figure 2A–C).
Allergenic functionality of the HSA conjugates was demon-
strated by mRBL-assay using DF/DF5der/DF-metabolite-specific
mouse antisera. HPSEC-derived fractions containing DF-HSA
monomer (5.0 DF/HSA) or DF-HSA aggregate (9.5 DF/HSA)
and unfractionated DF-HSA (7.6 DF/HSA) were analyzed in a
dilution series from 0.25 ng/ml to 12.5 mg/ml. As shown in
Figure 2D, FceRI-crosslinking capacity of the DF-HSA conjugates
was independent of aggregation state, a plateau was reached at
0.25 mg/ml, and the bell-shaped dose-response curve extended
over .3 orders of magnitude. Further experiments were
conducted with unfractionated conjugates only and 1 mg/ml was
determined adequate (center of bell-shaped dose-response curve)
to investigate IgE-mediated degranulation. All HSA conjugates
had functional IgE receptor-crosslinking capacities at this
concentration as shown in Figure 2E. Comparability of mediator
release assays using RBL-2H3 and RBL-30/25 cells for determi-
nation of specific IgE in murine and human sera has been shown
previously [24].
Potential cytotoxicity of DF/DF5der/DF-metabolite-HSA was
controlled in BAT by whole blood basophils activated with 10 mg/
ml anti-human IgE in presence of 1 or 20 mg/ml conjugate.
Reactivity of basophils in costimulated samples was not affected
compared to positive stimulation control (taken as 100% reactivity),
showing that HSA conjugates were not cytotoxic (Figure 2F).
Hapten-HSA conjugates as tools to detect drug-specific
antibody responses
Four approaches were used to investigate antibody responses
against DF and metabolites thereof. Antibodies in serum were
determined by ELISA and mediator release assay. Fifty-nine
patient sera and sera from six DF-tolerant controls were tested in
ELISA for DF/DF5der/DF-metabolite-specific IgE, IgG1 and
IgG4 antibodies. Only two sera showed IgE reactivities, one
against DF-HSA and the other against DF5der-HSA. Surprisingly,
one of these sera was from a DF-tolerant control. IgG-reactivities
against DF-, 49OH-DF-, 5OH-DF-, and 495diOH-DF-HSA could
be observed in seven patients (five DF patients, two NSAIDs
patients) and were mainly of the IgG4 subtype. Three of these
patients with positive IgG results had a history of severe
No IgE in DF Hypersensitivity
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IgG4 against DF-, 49OH-DF-, and 495diOH-DF-HSA could be
detected. No antibody reactivity could be detected for 39OH-DF-
and 39OH49metO-DF-HSA conjugates. Results of observed
reactivities are summarized in Table 1.
Mediator release assay with RBL-703/21 cells was performed as
this method may be more sensitive for the detection of low levels of
drug-specific IgE antibodies. Sera from 39 patients (26 DF
patients, 13 NSAIDs patients) including all three individuals with
grade IV anaphylactic reactions were analyzed. Five sera had to be
excluded and results of eight sera were ambiguous, as viabilities of
huRBL cells were #20% and #45%, respectively. Upon
stimulation with all hapten-HSA conjugates no b-hexosaminidase
release above background (.9.5%) was observed with any of the
tested patients9 sera (n=26).
Reactivity of cell-bound antibodies was assayed by BAT and
CAST in selected patients (i) with ,2 years interval between
hypersensitivity reactions and present study as sensitization to
drugs was shown to be lost with time [25] and (ii) without
immunomodulatory medication. Basophils from 19 patients (15
DF patients, four NSAIDs patients) and three DF-tolerant controls
were analyzed by flow cytometry for surface-bound DF/DF-
metabolite-specific IgE. Furthermore, basophils of all three
selective DF-hypersensitive and provocation test-positive patients
(#52, 53, and 58) were stimulated with the linkage variant,
DF5der-HSA (Table S2). DF patient #20 was excluded from
evaluation because basophils were not responsive to positive
stimulation control, NSAIDs patient #54 because of high
activation background (44.5%). DF/DF5der/DF-metabolite-
HSA did not cause CD63 upregulation in basophils of the
remaining 17 patients indicating lack of membrane-bound drug-
specific IgE.
De novo production of sLTs was measured in supernatants of
human peripheral blood mononuclear cells (PBMCs) from 19
patients (15 DF patients, four NSAIDs patients) and three DF-
tolerant controls after stimulation with hapten-HSA conjugates
(1 mg/ml). Only with PBMCs of DF patient #58 a slightly
elevated sLT value of 194 pg/ml in response to 39OH-DF-HSA
was observed (Table S2).
Discussion
Hypersensitivities caused by a single NSAID with concomitant
tolerance to other NSAIDs clearly argue against a pharmacoki-
netic imbalance as the driving mechanism. Based on this
assumption we sought to carefully define the phenotype of DF-
hypersensitive patients in order to investigate the possible
involvement of drug-specific immune responses. Due to the risk
of anaphylaxis, in the present study we followed current
recommendations [26] and did not perform double-blind
placebo-controlled drug challenges. Exceptions involve a few
patients who have been challenged with DF during their individual
diagnosis procedure. In order to distinguish individuals selectively
reactive to DF but tolerant to other NSAIDs (DF patients) from
multiple NSAIDs-reactive subjects, patients were subdivided into
two groups according to history and OPT with alternative
NSAIDs. Interestingly, a higher percentage of DF patients
displayed more severe (grade III/IV) reactions than the multiple
NSAIDs-reactive group. Positive skin tests found in three patients
from both groups confirmed the low predictive value of using
unhaptenized drugs for diagnosis. In this respect, the need for in
vitro diagnostics has been recently pointed out by the EAACI/
ENDA task force for classification, diagnosis, and management of
NSAIDs hypersensitivity [4].
As the observed specificity in DF patients is suspected to be
immune-mediated, drug-specific antibody responses were investi-
gated. Because haptenation and drug metabolism may play a role
we used a panel of HSA conjugates of drug and metabolites. IgE in
serum samples and bound to basophils was determined in DF and
multiple NSAIDs patients, as well as in DF-tolerant controls.
Figure 1. Coupling strategy. Bioactivation resulting in haptenation was mimicked by linkage of native DF (A) via position 5 or (B) via position 1 and
linkage of five Phase I DF-metabolites (C) 39OH-DF, (D) 49OH-DF, (E) 5OH-DF, (F) 495diOH-DF, (G) 39OH49metO-DF via position 1 to HSA as protein carrier.
doi:10.1371/journal.pone.0013707.g001
No IgE in DF Hypersensitivity
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except for one DF patient showing marginal levels of DF5der-
specific IgE in ELISA. Interestingly, IgG reactivity against DF,
49OH-DF-, 5OH-DF-, and 495diOH-DF-HSA was observed in
some individuals highlighting the immunogenic potential of the
investigated molecules. This is in line with reports on formation of
erythrocyte neoantigens and anti-49OH-DF-specific antibodies in
patients with DF-induced immunohemolytic anemia [12,27] and
reports on oxidized 5OH-DF as antigenic determinant for T cell
proliferation in metabolite-immunized mice [11]. Thus, the
importance of investigating bioactivation and metabolism in DF
hypersensitivity is clearly demonstrated. Linkage of DF/DF-
Figure 2. Characterization of hapten-HSA conjugates. (A) Coupling degree of eluting HPSEC fractions derived from hapten-HSA conjugates
was determined from (B) the ratio of refractive index (black) to UV signal (gray) resulting in (C) several haptens per carrier molecules for all conjugates
compared to respective mock controls; determined coupling degree for total, monomeric, and aggregated HPSEC fractions are illustrated in black,
light, and dark gray, respectively. (D) Determination of optimal concentration of DF-HSA conjugate for FceRI-crosslinking/mediator release;
determined values for total, monomeric, and aggregated HPSEC fractions are illustrated in black, light, and dark gray, respectively, mock controls in
white. (E) All hapten-HSA conjugates (dark gray) showed mediator release (n=1–4) from rat basophil leukemia cells when incubated with sera from
immunized mice; mock controls in light gray. (F) Investigation of cytotoxicity of hapten-HSA conjugates coincubated at 1 (dark gray) and 20 mg/ml
(light gray) with anti-IgE by basophil activation test (100% without conjugate).
doi:10.1371/journal.pone.0013707.g002
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chemical modification of proteins via reactive acyl glucuronides,
which is the most important mechanism of detoxification [10].
The glucuronidation process was shown to bioactivate drugs
leading to covalent binding to proteins or formation of conjugates
[28,29]. Alternatively, linkage of DF via position 5 mimics
potential drug-protein-conjugates resulting from reactive Phase
II metabolic intermediates that escaped detoxification by gluta-
thione [30,31]. In this study, no evidence for DF/DF5der/DF-
metabolite-specific serum IgE was found in ELISA or mediator
release assay. However, these findings have not excluded all the
possibilities of IgE-mediated reactions to DF yet. In fact, we
observed that basophils from birch-allergic donors collected off-
season were reactive in BAT, but the corresponding pollen-specific
serum IgE was negative or borderline when determined by ELISA
(data not shown). As basophils have been recently shown to be key
players in the immune system [32], we investigated DF/DF5der/
DF-metabolite-specific IgE bound on patients’ basophils by BAT
and sLT production. These methods analyze two consecutive
cellular events in response to IgE-receptor crosslinking: upregula-
tion of basophil activation markers due to degranulation followed
by release of preformed mediators and production of sLTs as
broncho- and vasoactive mediators of the allergic reaction.
However, neither of these two methods provided convincing
evidence for the existence of drug/metabolite-specific IgE
antibodies.
This study represents the first comprehensive mechanistic
investigation of a potential IgE-mediated mechanism in selective
DF hypersensitivity. In addition to the drug itself the most relevant
DF metabolites were examined. Two known DF metabolites were
not included in this study. First, an alternative side product of the
reactive DF acyl glucuronide, which was described for the NSAID
tolmetin [33]. However, immunization of mice with tolmetin acyl
glucuronide led to the production of antibodies cross-reactive to
tolmetin [34], suggesting that this type of metabolites share
relevant epitopes with the parental NSAIDs. Second, derivatives of
reactive 29,39-oxide resulting in 29-OH-monofenac linked to
glutathione via position 39, which were found in human liver
microsomal preparations [35]. In principle, such metabolites
might escape the glutathione detoxification process and form
haptens, however, no protein conjugates have been described so
far. It is noteworthy that mice immunized with DF or the five
Phase I metabolites responded with IgE cross-reactive to all
haptens included in this study (data not shown). Consequently, we
are confident that the approach of the present study should allow
detection of IgE specific for acyl glucuronides of DF as well as not
yet identified structurally closely related DF metabolites.
In conclusion, our findings provide evidence that antibodies, in
particular IgE, are not involved in DF hypersensitivity. It is
possible that the clinical conditions of certain individuals at the
time of medication might influence reactivity to the drug, adding
another level of complexity to this pathology. This may include
anaphylactic progression due to acute inflammation, potential
subclinical diseases, interactions between medications, or even
psychogenic effects. At present, a pathomechanism encompassing
these effects remains speculative.
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